Skip to content
Company Analysis

Burning Rock Biotech Limited BNR

A comprehensive view of key metrics, scores, and financial health for Burning Rock Biotech Limited

Overview of Burning Rock Biotech Limited

BNR NGM
Healthcare Diagnostics & Research Micro Cap
Burning Rock Biotech Limited (BNR), is a Micro Cap company, in the Diagnostics & Research industry, last closed at $16.01, about 229.0% undervalued vs fair value, +175.9% 1Y return, ranked 479/1111 in sector.
$16.01
-29.93%
As of March 13, 2026
Previous close • Vol 90d: 157.0%
52-Week Range
Market Cap
$172.37M
Enterprise Value
$-258.44M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Burning Rock Biotech Limited.

Top Beats
No strong beats yet

Quick Facts

Website https://www.brbiotech.com
HQ Guangzhou
Employees 674
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$41
$53
$66
Current: $16.01 +229% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$515.8M
-4%%
Gross Profit
$362.4M
-0.2%%
Operating Income
$-322.4M
51.8%%
Net Income
$-346.6M
47%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
28.3%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Burning Rock Biotech Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
43
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing BNR's balance between Growth (33.1%), Profitability (30.9%), and Safety (36.0%). Growth 33% Safety 36% Profitability 31%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

34th percentile vs peers
35
Key Signals
EPS Growth YoY 47.2% 60p Revenue CAGR 3Y 0.5% 33p Rev Growth YoY -4.0% 17p
Strengths
  • Gross Profit Margin in top 20% of peers (70.3%, 94th percentile)
  • Strong liquidity position vs peers
Risks
  • Rev Growth Yoy in bottom 20% of peers (-4.0%)

Profitability

32th percentile vs peers
32
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

37th percentile vs peers
38
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Burning Rock Biotech Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$52.68
- - -
+229.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info